BioLineRx Reports Year End 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
BioLineRx (BLRX) PT Lowered to $2 at Maxim Group
March 6, 2018 1:21 PM ESTMaxim Group lowered its price target on BioLineRx (NASDAQ: BLRX) to $2.00 (from $3.00) while maintaining a Buy rating.
Analyst Jason McCarthy commented, "BiolineRx reported 4Q17 with a net loss of $7.4M and ended the period with $50M in cash on the balance sheet,... More



